Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 28, 2025
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FINCoVac 2.1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Cevec
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Rokote Laboratories Licenses Cevec’s Cap® Ad Technology For Vaccine Manufacturing
Details : Under the agreement, CEVEC has granted ROKOTE a non-exclusive rights to use the CAP® Ad platform for the manufacturing of adeno-based vaccines (FINCoVac 2.1) for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 20, 2022
Lead Product(s) : FINCoVac 2.1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Cevec
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : FINCoVac 2.0
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Exothera
Deal Size : Undisclosed
Deal Type : Partnership
Details : The FINCoVac vaccine is designed to program the nasopharyngeal cells to produce immune response-inducing modified SARS-CoV-2-viral spike protein. FINCoVac 2.0 represents an easy-to-administer booster for those who are already fully vaccinated with other ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 04, 2022
Lead Product(s) : FINCoVac 2.0
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Exothera
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rokote Lab’s COVID-19 Nasal Vaccine on Financing Fence Before Phase I Trials
Details : Rokote’s nasal spray vaccine uses an adenovirus to carry a cloned DNA strand to nasopharyngeal cells, causing them to produce a protein that launches an immune response.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 19, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable